Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

PHASE2CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Obesity
Interventions
DRUG

Placebo

placebo pramlintide and placebo metreleptin twice daily

DRUG

Pramlintide and Metreleptin

Subcutaneous injection, twice daily

Trial Locations (33)

Unknown

Research Site, Birmingham

Research Site, Phoenix

Research Site, Santa Rosa

Research Site, Walnut Creek

Research Site, Denver

Research Site, Jacksonville

Research Site, Miami

Research Site, Plantation

Research Site, Atlanta

Research Site, Chicago

Research Site, Springfield

Research Site, Kansas City

Research Site, Baton Rouge

Research Site, Boston

Research Site, Edina

Research Site, St Louis

Research Site, Butte

Research Site, New York

Research Site, Cincinnati

Research Site, Columbus

Research Site, Eugene

Research Site, Medford

Research Site, Anderson

Research Site, Greer

Research Site, Mt. Pleasant

Research Site, Nashville

Research Site, Austin

Research Site, Dallas

Research Site, San Antonio

Research Site, Salt Lake City

Research Site, Norfolk

Research Site, Bellingham

Research Site, Olympia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY